Abstract: Soluble, secreted tumor necrosis factor receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise one cysteine-rich repeat that is homologous to other tumor necrosis factor receptors, such as transmembrane activator and CAML-interactor (TACI). The polypeptides may be used for detecting ligands, agonists and antagonists. The polypeptides may also be used in methods that modulate B cell activation.
Abstract: Nucleic acid molecules that comprise modified open reading frames providing increased expression of the encoded active BoNT/E in a heterologous cell, expression constructs and cells comprising such nucleic acid molecules and methods useful for expressing the encoding active BoNT/E from such nucleic acid molecules, expression constructs and cells.
Type:
Grant
Filed:
June 9, 2005
Date of Patent:
November 2, 2010
Assignee:
Allergan, Inc.
Inventors:
Lance E. Steward, Marcella A. Gilmore, Ester G. Fernandez-Salas, Shengwen Li, Ronald G. Miller, Kei Roger Aoki
Abstract: The present invention relates to a genetically engineered P30 antigen and a combination or mixture of antigens (e.g., the genetically engineered P30 antigen and P35) that may be used in the detection of IgM and/or IgG antibodies to Toxoplasma gondii. Furthermore, the present invention also relates to methods of using this genetically engineered P30 antigen and combination of antigens, antibodies raised against this genetically engineered P30 antigen and combination of antigens, as well as kits and vaccines containing the genetically engineered P30 antigen and antigens present in the combination.
Type:
Grant
Filed:
September 24, 2007
Date of Patent:
November 2, 2010
Inventors:
Gregory T. Maine, Chandu B. Patel, Sanford R. Ginsburg, Timothy R. Bliese
Abstract: A method for the laboratory determination of prosthetic infections is described. This method, performed on biological fluids isolated from patients, is based on the detection of antibodies specific for the polysaccharides produced by bacteria colonizing prosthetic devices.
Type:
Grant
Filed:
May 1, 2002
Date of Patent:
October 5, 2010
Assignee:
BRACCO S.p.A.
Inventors:
Maria Cristina Thaller, Gianmaria Rossolini, Laura Selan, Claudio Passariello
Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.
Abstract: The invention belongs to the field of animal health and in particular the causative agent of a new bacterial poultry disease, Gallibacterium. The invention provides said Gallibacterium bacteria, vaccine comprising inactivated Gallibacterium, and a method of immunizing to prevent disease in poultry.
Type:
Grant
Filed:
February 25, 2009
Date of Patent:
September 14, 2010
Assignee:
Boehringer Ingelheim Vetmedica S.A. DE C.V.
Inventors:
Raul Campogarrido, Carlos Gonzalez-Hernandez, Vaithianathan Sivanandan, Maria Elena Vazquez
Abstract: The present invention provides nucleic acid sequences encoding a modified leukotoxin protein, wherein the modification comprises the removal of nucleic acid sequences encoding amino acids within hydrophobic transmembrane domains of full length leukotoxin protein, preferably from Mannheimia haemolytica. The modified leukotoxin proteins are useful in vaccine compositions effective against Mannheimia haemolytica in animals.
Type:
Grant
Filed:
October 23, 2007
Date of Patent:
September 7, 2010
Assignee:
University of Guelph
Inventors:
Reggie Y. C. Lo, Patricia E. Shewen, Raymond W. H. Lee, Doug Hodgins, Judith N. Strommer
Abstract: A method for treating a virus-containing sample, characterized by treatment of a virus-containing sample with a treatment solution containing (1) an anionic surfactant and (2) an amphoteric surfactant, nonionic surfactant or protein denaturant; a virus assay method using said treating method; a method for treating a virus-containing sample, characterized by treatment of a virus-containing sample with a treatment solution containing (1) a chaotropic ion and (2) an acidifying agent; a virus assay method using said treating method; a virus assay method, characterized in that a virus antigen and a virus antibody are measured based on their binding to their probe in the presence of a surfactant with an alkyl group of 10 or more carbon atoms and a secondary, tertiary or quaternary amine, or a nonionic surfactant, or of both of them; and a monoclonal antibody and a hybridoma producing the same for carrying out said method.
Abstract: Soluble, secreted tumor necrosis factor receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise one cysteine-rich repeat that is homologous to other tumor necrosis factor receptors, such as transmembrane activator and CAML-interactor (TACI). The polypeptides may be used for detecting ligands, agonists and antagonists. The polypeptides may also be used in methods that modulate B cell activation.
Type:
Grant
Filed:
July 20, 2006
Date of Patent:
August 10, 2010
Assignee:
Zymogenetics, Inc.
Inventors:
Jane A. Gross, Wenfeng Xu, Karen L. Madden, David P. Yee
Abstract: Sequences encoding two immunoreactive glycoproteins were cloned from Ehrlichia canis (p153 gene) and Ehrlichia chaffeensis (p156 gene). These two glycoproteins are species-specific immunoreactive orthologs that are useful as subunit vaccines and for serologic and molecular diagnostics for E. canis and E. chaffeensis.
Abstract: This invention relates to vaccines and methods for protecting dogs against disease caused by Bordetella bronchiseptica. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by Bordetella bronchiseptica, canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, enteritis caused by canine coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused by Leptospira Bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae or Leptospira pomona. The vaccines of the present invention include a Bordetella bronchiseptica p68 antigen.
Type:
Grant
Filed:
November 20, 2007
Date of Patent:
June 15, 2010
Assignee:
Pfizer Inc.
Inventors:
Paul J. Dominowski, Joseph C. Frantz, Richard L. Krebs, Shelly L. Shields, Robert Greg Sorensen
Abstract: Described herein is a composition useful for inducing expression of genes whose expression is under control of an inducible promoter sequence and methods for the compositions preparation and use.
Type:
Grant
Filed:
September 10, 2003
Date of Patent:
May 11, 2010
Assignee:
Danisco US Inc.
Inventors:
George R. England, Aaron Kelley, Colin Mitchinson
Abstract: Methods for treating or preventing infections from coagulase-negative staphylococci using proteins and polypeptides from coagulase-negative staphylococcal bacteria such as S. epidermidis, including proteins designated SdrF, SdrG and SdrH, and their effective fragments such as their respective A domains, are provided. Methods are also provided wherein antibodies that recognize the SdrG protein or its ligand binding A region are used to treat or prevent staphylococcal infection, and these methods can also be utilized to prevent the formation of infections on indwelling medical devices.
Type:
Grant
Filed:
April 4, 2006
Date of Patent:
May 4, 2010
Assignees:
The Provost Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth Near Dublin, The Texas A & M University System
Inventors:
Timothy J. Foster, Kirk McCrea, Magnus A. O. Hook, Stacey Davis, Deirdre Ni Eidhin, Orla Hartford
Abstract: The invention relates to methods for the accumulation and retention of immune-enhancing, bacterial-derived ribonucleotides smaller than 10,000 Daltons (ORN<10 kDa) in bacteria that are produced when bacteria are grown naturally, allowing the pH of the growth medium to become acidic. The immune-enhancing, bacterial-derived ribonucleotides (ORN) and bacteria comprising ORN are useful in the preparation of animal feed or animal drinking water as well as for use in enhancing the immune system of an animal and/or its resistance to infection. The invention also discloses methods of preventing the loss of ORN during bacterial production and storage as well as methods to aid in the release of ORN when consumed by an animal.
Abstract: The present invention provides a composition comprising hydrolysed milk casein and, preferably non-hydrolysed whey protein in a ratio from 9:1 to 1:1 (on dry weight), which is a clear liquid at pH 4 when dissolved or present in water in an amount of 40 g/liter at 10° C.
Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.
Abstract: Provided are natural and synthetic immunomodulatory polymeric antigens (SPAs), compositions containing SPAs, and methods of using these natural and synthetic SPAs and compositions to prevent or treat inflammatory pathologies.
Type:
Grant
Filed:
March 7, 2003
Date of Patent:
December 8, 2009
Assignee:
Eli Lilly and Company
Inventors:
Kathleen Ann Taylor, Larry Chris Blaszczak, Neil Thomas Blackburn
Abstract: A chemical conjugate for treating a nerve cell related disorder is provided. This conjugate includes an active or inactive Clostridial toxin having specificity for a target nerve cell. The toxin is conjugated to a drug or other bioactive molecule without affecting the toxin's ability to enter the target nerve cell.
Type:
Grant
Filed:
September 28, 2000
Date of Patent:
December 8, 2009
Assignee:
Invent DCU Limited
Inventors:
James Oliver Dolly, Larry Allen Wheeler, Kei Roger Aoki, Michael Elwood Garst
Abstract: A method of identifying a molecule capable of inducing death of a bacterial cell which includes exposing toxin and antitoxin polypeptides of a toxin-antitoxin pair produced by the bacterial cell to a plurality of molecules, and identifying a molecule of the plurality of molecules capable of preventing or disrupting binding between the antitoxin and said toxin polypeptides, thereby identifying the molecule capable of inducing death of the bacterial cell.
Abstract: The present invention is directed to heat shock proteins from Mycobacterium leprae as well as their encoding polynucleotides and vectors and host cells containing these polynucleotides. These heat shock proteins and their encoding polynucleotides are useful in detection of Mycobacterium leprae. In addition, the heat shock protein can be used as an adjuvant in a pharmaceutical composition containing an antigen to induce or enhance the immune response against the antigen. Further, the heat shock protein may be used to treat atopic conditions or as a vaccine against Mycobacterium leprae. Alternatively, the heat shock protein can be used to form a fusion protein with an antigen to induce or enhance the immune response against the antigen.